keyword
MENU ▼
Read by QxMD icon Read
search

orbera

keyword
https://www.readbyqxmd.com/read/29071537/major-gastric-haemorrhage-after-intragastric-balloon-insertion-case-report
#1
Romy J Granek, Michael W Hii, Salena M Ward
Intragastric balloons are a minimally invasive option for weight loss. They are generally well tolerated and rarely associated with serious adverse events. We report a case of major upper gastrointestinal haemorrhage after insertion of an Orbera® intragastric balloon.
October 25, 2017: Obesity Surgery
https://www.readbyqxmd.com/read/28965290/endoscopic-treatments-for-obesity
#2
REVIEW
Gregory Pajot, Gerardo Calderon, Andrés Acosta
Purpose of review Endoscopic bariatric therapy (EBT) is a rapidly developing area that has now seen FDA approval of six endoscopic bariatric devices and procedures and there are a number of other novel EBTs progressing through various stages of development with newly published findings. This paper aims to assist readers in either selecting an appropriate therapy for their patient or deciding to incorporate these therapies into their practice. This paper provides an updated review of the available data on EBTs, both FDA approved and not, with a particular focus on effectiveness and safety, as well as guidance for discussing with your patient the decision to use endoscopic therapies...
December 2017: Current Treatment Options in Gastroenterology
https://www.readbyqxmd.com/read/28740414/the-role-of-endoscopic-therapy-in-obesity-management-intragastric-balloons-and-aspiration-therapy
#3
REVIEW
Nitin Kumar, Shelby Sullivan, Christopher C Thompson
Weight management is increasingly incorporating endoscopic bariatric therapy (EBT). As the global burden of obesity and its comorbidities has increased, it is evident that novel therapeutic approaches will be necessary to address the obesity epidemic. EBTs offer greater efficacy than diet and lifestyle modification and lower invasiveness than bariatric surgery. The US Food and Drug Administration has approved two intragastric balloons and aspiration therapy for the treatment of obesity: Apollo Orbera is indicated for the treatment of Class I and Class II obesity, Re Shape Integrated Dual Balloon system is indicated for the same range with a comorbidity, and Aspire Bariatrics AspireAssist is approved for patients with a body mass index of 35-55 kg/m(2)...
2017: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
https://www.readbyqxmd.com/read/28707286/intragastric-balloon-treatment-for-obesity-review-of-recent-studies
#4
REVIEW
Chinara M Tate, Allan Geliebter
INTRODUCTION: The FDA recently approved three intragastric balloon (IGB) devices, ReShape, ORBERA™, and Obalon for treatment of obesity. Given the high cost, complication risk, and invasiveness of bariatric surgery, IGB treatment may present a safer and lower cost option for weight reduction. IGBs are generally placed in the stomach endoscopically for up to 6 months to reduce gastric capacity, enhance feelings of fullness, and induce weight loss. The mechanism of action likely involves stimulation of gastric mechanoreceptors triggering short-acting vagal signals to brain regions implicated in satiety...
July 13, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28421456/filling-the-void-a-review-of-intragastric-balloons-for-obesity
#5
REVIEW
Patrick Laing, Tuan Pham, Linda Jo Taylor, John Fang
Endoscopic bariatric therapies are predicted to become much more widely used in North America for obese patients who are not candidates for bariatric surgery. Of all the endoscopic bariatric therapies, intragastric balloons (IGBs) have the greatest amount of clinical experience and published data supporting their use. Three IGBs are FDA approved and are now commercially available in the USA (Orbera, ReShape Duo, and Obalon) with others likely soon to follow. They are generally indicated for patients whose BMI ranges from 30 to 40 mg/kg(2) and who have failed to lose weight with diet and exercise...
June 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28301947/multicenter-study-on-the-safety-of-bariatric-endoscopy
#6
Eduardo Espinet Coll, Javier Nebreda Durán, Gontrand López-Nava Breviere, Julio Ducóns García, Manuel Rodríguez-Téllez, Javier Crespo García, Carlos Marra-López Valenciano
INTRODUCTION: Bariatric endoscopy includes a series of specific techniques focused on the management of obese patients. As a quality criterion, safety as expressed by a minimal incidence of serious complications is required in addition to efficacy. METHODS: A descriptive, retrospective, multicenter review of the experience recorded at seven hospitals included in the Grupo Español de Endoscopia Bariátrica (GETTEMO) in order to document the incidence, cause, and resolution (including legal consequences) of serious complications reported for each bariatric technique, and according to endoscopist expertise...
May 2017: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/28285471/the-influence-of-the-orbera-intragastric-balloon-filling-volumes-on-weight-loss-tolerability-and-adverse-events-a-systematic-review-and-meta-analysis
#7
Nitin Kumar, Fateh Bazerbachi, Tarun Rustagi, Thomas R McCarty, Christopher C Thompson, Manoel P Galvao Neto, Natan Zundel, Erik B Wilson, Christopher J Gostout, Barham K Abu Dayyeh
BACKGROUND: The Orbera intragastric balloon (IGB) has been approved by the US Food and Drug Administration for use in patients with a body mass index (BMI) between 30 and 40 kg/m(2) and is in wide use worldwide as a primary and bridge obesity management tool. The balloon filling volume (BFV) ranges between 400 and 700 mL of saline. Our objective was to determine whether there is an association between BFV and clinically relevant endpoints, namely weight loss outcomes, balloon tolerability, and adverse events...
September 2017: Obesity Surgery
https://www.readbyqxmd.com/read/28017964/intragastric-balloon-as-an-adjunct-to-lifestyle-intervention-a-randomized-controlled-trial
#8
A Courcoulas, B K Abu Dayyeh, L Eaton, J Robinson, G Woodman, M Fusco, V Shayani, H Billy, D Pambianco, C Gostout
BACKGROUND/OBJECTIVES: This trial evaluated the safety and effectiveness of the Orbera Intragastric Balloon as an adjunct to lifestyle intervention. SUBJECTS/METHODS: In this multicenter, randomized, open-label clinical trial, 255 adults with a body mass index of 30-40 kg m(-)(2) were treated and outcomes were assessed up to 12 months. Participants were randomized to endoscopic placement of an intragastric balloon plus lifestyle or lifestyle intervention alone...
March 2017: International Journal of Obesity: Journal of the International Association for the Study of Obesity
https://www.readbyqxmd.com/read/26305524/reshape-and-orbera-two-gastric-balloon-devices-for-weight-loss
#9
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
August 31, 2015: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/26240686/endoscopic-therapy-for-weight-loss-gastroplasty-duodenal-sleeves-intragastric-balloons-and-aspiration
#10
REVIEW
Nitin Kumar
A new paradigm in the treatment of obesity and metabolic disease is developing. The global obesity epidemic continues to expand despite the availability of diet and lifestyle counseling, pharmacologic therapy, and weight loss surgery. Endoscopic procedures have the potential to bridge the gap between medical therapy and surgery. Current primary endoscopic bariatric therapies can be classified as restrictive, bypass, space-occupying, or aspiration therapy. Restrictive procedures include the USGI Primary Obesity Surgery Endolumenal procedure, endoscopic sleeve gastroplasty using Apollo OverStitch, TransOral GAstroplasty, gastric volume reduction using the ACE stapler, and insertion of the TERIS restrictive device...
July 25, 2015: World Journal of Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/26232362/asge-bariatric-endoscopy-task-force-systematic-review-and-meta-analysis-assessing-the-asge-pivi-thresholds-for-adopting-endoscopic-bariatric-therapies
#11
REVIEW
Barham K Abu Dayyeh, Nitin Kumar, Steven A Edmundowicz, Sreenivasa Jonnalagadda, Michael Larsen, Shelby Sullivan, Christopher C Thompson, Subhas Banerjee
The increasing global burden of obesity and its associated comorbidities has created an urgent need for additional treatment options to fight this pandemic. Endoscopic bariatric therapies (EBTs) provide an effective and minimally invasive treatment approach to obesity that would increase treatment options beyond surgery, medications, and lifestyle measures. This systematic review and meta-analysis were performed by the American Society for Gastrointestinal Endoscopy (ASGE) Bariatric Endoscopy Task Force comprising experts in the subject area and the ASGE Technology Committee Chair to specifically assess whether acceptable performance thresholds outlined by an ASGE Preservation and Incorporation of Valuable endoscopic Innovations (PIVI) document for clinical adoption of available EBTs have been met...
September 2015: Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/22805941/isolation-and-characterisation-of-aerobic-endospore-forming-bacilli-from-sugarcane-rhizosphere-for-the-selection-of-strains-with-agriculture-potentialities
#12
Teresa de Los Milagros Orberá Ratón, Ricardo Yano, Odalys Rodríguez Gámez, Eny Iochevet Segal Floh, Manuel de Jesús Serrat Díaz, Heloíza Ramos Barbosa
Eighteen aerobic endospore forming strains were isolated from sugarcane rhizosphere in N-free medium. A phenotypic description and analysis of the 5' end hypervariable region sequences of 16S rRNA revealed a high diversity of Bacillus and related genera. Isolates were identified, and four genera were obtained: seven strains belonged to Bacillus (Bacillaceae family), four belonged to Paenibacillus, six belonged to Brevibacillus and one strain was identified as Cohnella (Paenibacillaceae family). Four Brevibacillus strains showed in vitro inhibitory activity against plant pathogens fungi Curvularia and Fusarium...
April 2012: World Journal of Microbiology & Biotechnology
https://www.readbyqxmd.com/read/15458357/-molecular-identification-methods-of-yeasts-of-biotechnological-interest
#13
REVIEW
Teresa Orbera-Ratón
Yeasts have numerous applications in modern and traditional biotechnology. They take place in production of food, unicellular protein and products with added value, and in the last decades they have been incorporated to the biotechnology industry as host in the production of eukaryotes proteins. Apart from their advantages, some genera are the causes of mycosis on man and in some cases, are opportunistic pathogens associated to diseases such as HIV. They are also agents responsible for the damaging of fresh and elaborated food for human consumption...
March 2004: Revista Iberoamericana de Micología
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"